KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Notes Payables: 2022

Historic Notes Payables for Supernus Pharmaceuticals (SUPN) over the last 1 years, with Dec 2022 value amounting to $402.0 million.

  • Supernus Pharmaceuticals' Notes Payables was N/A to $402.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $402.5 million, marking a year-over-year change of. This contributed to the annual value of $402.0 million for FY2022, which is N/A change from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Notes Payables of $402.0 million as of FY2022.
  • In the past 5 years, Supernus Pharmaceuticals' Notes Payables registered a high of $402.0 million during FY2022, and its lowest value of $402.0 million during FY2022.
  • Its 1-year average for Notes Payables is $402.0 million, with a median of $402.0 million in 2022.